( KANSAS CITY Mo.--(BUSINESS WIRE)--Apr ...)First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS),Health

KANSAS CITY, Mo.--(BUSINESS WIRE)--Apr 11, 2007 - A comparison of the long-term economic outcomes of four immunomodulatory drug therapies combined with symptom management versus symptom management alone revealed that COPAXONE(R) (glatiramer acetate injection) was the most cost-effective treatment strategy for relapsing-remitting multiple sclerosis (RRMS). The study provides the first pharmacoeconomic evaluation of the cost-effectiveness of multiple sclerosis (MS) therapies that includes long-term treatment outcomes and costs associated with missed days from work. The study also evaluated the impact of neutralizing antibody (NAb) development in pharmacoeconomic measures among patients treated with the interferon beta (IFN-(beta)) class of drugs. The findings of the study, "Cost-effectiveness of Four Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis: A Markov Model Based on Long-term Clinical Data," were published in the April issue of the Journal of Managed Care Pharmacy.

"The recent availability of data demonstrating the long-term treatment outcomes of immunomodulatory therapies in MS allowed us to assess the cost-effectiveness of various RRMS treatment strategies. Findings of this study indicated that of the four therapies used to manage MS and in comparison with symptom management alone, the use of COPAXONE(R) was the best strategy in terms of outcomes and costs," said Kenneth Johnson, M.D., professor of Neurology and director of the Maryland Center for Multiple Sclerosis, School of Medicine, University of Maryland. "A treatment that reduces relapses or slows the progression of disability, as measured by the Expanded Disability Status Scale (EDSS), may assist in lowering resource utilization and in turn help to offset the cost of therapy," Johnson added.

Cost-effectiveness and cost-utility analyses are useful tools for assessing the relationship between added costs and potential ben
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model